Open company graph database — free web & API
Login

Otsuka America Pharmaceutical, Inc

大塚アメリカ製薬株式会社Alias
Ticker
—
Listed market
—
Country
United States of America
Employees (non-consolidated)
—
Related companies
9
§01

Basic information

BASIC
Head office
508 Carnegie Center Dr, Princeton, NJ 08540, United States
Chief executive
Employees (non-consolidated)
Employees (consolidated)
Start date
End date
§02

Websites

1 DOMAINS
§03

Business

6
ProductsProfessional CommunitiesPatient ResourcesFamily ResourcesMedical InformationBrand Portal
§04

Related companies

9 COMPANIES
Company name Group Parent Subsidiary Customer Supplier Alliance Bank Shareholder
EN Otsuka Pharmaceutical Co., Ltd.
Group Parent
Otsuka America, Inc.
Group Parent
Otsuka Pharmaceutical Development & Commercialization, Inc.
Group Subsidiary
Avanir
Group Subsidiary
Akebia Therapeutics, Inc.
Alliance
Novartis AG
Alliance
Pfizer
Alliance
Sanofi
Alliance
Verily
Alliance
Names without a link are companies not yet registered in OpenBizGraph
§05

Network

NETWORK
Drag to move · click to open
§06

History

9 EVENTS

FDA approves ABILIFY (aripiprazole)Sources

FDA approves SAMSCA (tolvaptan)Sources

FDA approves ABILIFY MAINTENA (aripiprazole)Sources

FDA approves REXULTI (brexpiprazole)Sources

FDA approves ABILIFY MYCITE (aripiprazole tablets with sensor) Not commercially availableSources

FDA approves JYNARQUE (tolvaptan)Sources

FDA approves ABILIFY ASIMTUFII (aripiprazole) for extended release injectable suspensionSources

FDA approves VOYXACT (sibeprenlimab-szsi)Sources

FDA approved SIMTRIYO (centanafadine) Under U.S. Drug Enforcement Administration (DEA) scheduling reviewSources

§07

News

7 ARTICLES

Otsuka Launches Early Access Program for People with FUS-ALSSources

Otsuka has launched an early access program for ulefnersen for people with FUS-ALS. The program aims to facilitate early access to the investigational drug outside clinical trials and support patients with limited treatment options.

Otsuka Announces Phase 3 Ulefnersen Results for FUS-ALSSources

Otsuka's Ulefnersen showed significant improvement in FUS-ALS patients, supporting its potential to modify disease progression. The drug was well tolerated with mostly mild adverse events. Results will be discussed with regulatory authorities for potential expedited approval.

SIMTRIYO Phase 3b: ADHD & Anxiety GainsSources

New Phase 3b results demonstrate consistent improvements in ADHD and anxiety symptoms, executive function, and emotional dysregulation, as assessed by both clinicians and patients. The findings build on SIMTRIYO’s established ADHD clinical program and expand its profile in adults with comorbid anxiety disorders. The data are part of 26 Otsuka-sponsored abstracts presented at Psych Congress 2026, reflecting the company’s continued investment in CNS and psychiatric neuroscience research.

GlomCon & Otsuka Launch REIGNITESources

The REIGNITE Study is a multi‑year, longitudinal registry that will enroll more than 6,000 patients with IgA nephropathy to evaluate treatment patterns and health outcomes. The data generated will provide real‑world evidence to help shape future disease management and patient care.

VOYXACT Stabilizes Function in IgANSources

The Phase 3 VISIONARY study met its key secondary endpoint, showing an annualized eGFR slope of +0.3 mL/min/1.73 m²/year with VOYXACT versus –4.2 with placebo. VOYXACT is the first FDA‑approved IgAN treatment to demonstrate stabilization of kidney function over two years, with a safety profile comparable to placebo. The results support VOYXACT’s selective APRIL inhibition as a disease‑modifying approach that targets a key driver of IgA nephropathy.

VOYXACT Stabilizes eGFR Over 2 YearsSources

Otsuka will present Phase 3 VISIONARY data at GlomCon Hawaii 2026, showing that VOYXACT is the only APRIL inhibitor to achieve statistically significant eGFR stabilization over two years versus placebo. The results support kidney function preservation and halt disease progression in IgA nephropathy. These findings strengthen the evidence for selective APRIL inhibition as a safe, disease‑modifying therapy targeting underlying IgAN drivers.

Otsuka Reports Positive Phase 3 VISIONARY StudySources

VOYXACT® (sibeprenlimab-szsi), the first APRIL inhibitor to demonstrate statistically significant eGFR stabilization over two years, showed robust reductions in the risk of progression to kidney failure and improved kidney function in IgA nephropathy. The drug also received U.S. FDA accelerated approval in November 2025 for reducing proteinuria in adults with IgAN. These Phase 3 VISIONARY results complete the dataset and represent a milestone in Otsuka’s rolling submission of a supplemental Biologics License Application.

§09

Sources & updates

SOURCES
↑